Maverick Capital Ltd. Buys 292,176 Shares of NewAmsterdam Pharma Company N.V. $NAMS

Maverick Capital Ltd. grew its position in NewAmsterdam Pharma Company N.V. (NASDAQ:NAMS) by 15.4% in the 1st quarter, Holdings Channel reports. The institutional investor owned 2,186,402 shares of the company’s stock after purchasing an additional 292,176 shares during the period. Maverick Capital Ltd.’s holdings in NewAmsterdam Pharma were worth $69,987,000 at the end of the most recent quarter.

Several other large investors have also made changes to their positions in NAMS. Sei Investments Co. increased its position in NewAmsterdam Pharma by 35.6% in the first quarter. Sei Investments Co. now owns 55,637 shares of the company’s stock worth $1,781,000 after purchasing an additional 14,597 shares during the period. Mizuho Markets Cayman LP boosted its stake in shares of NewAmsterdam Pharma by 9.1% in the 1st quarter. Mizuho Markets Cayman LP now owns 52,227 shares of the company’s stock valued at $1,672,000 after purchasing an additional 4,348 shares during the last quarter. PNC Financial Services Group Inc. grew its position in shares of NewAmsterdam Pharma by 147.7% during the 1st quarter. PNC Financial Services Group Inc. now owns 9,119 shares of the company’s stock worth $292,000 after buying an additional 5,437 shares during the period. AlphaCentric Advisors LLC grew its position in shares of NewAmsterdam Pharma by 6.7% during the 1st quarter. AlphaCentric Advisors LLC now owns 14,656 shares of the company’s stock worth $469,000 after buying an additional 925 shares during the period. Finally, KBC Group NV bought a new stake in shares of NewAmsterdam Pharma during the first quarter worth approximately $37,000. Institutional investors and hedge funds own 89.89% of the company’s stock.

Analyst Ratings Changes

Several equities analysts recently weighed in on NAMS shares. Jefferies Financial Group restated a “buy” rating and issued a $45.00 price objective on shares of NewAmsterdam Pharma in a report on Monday, July 20th. Wall Street Zen upgraded shares of NewAmsterdam Pharma from a “sell” rating to a “hold” rating in a research report on Saturday, May 9th. Royal Bank Of Canada increased their price target on NewAmsterdam Pharma from $47.00 to $51.00 and gave the company an “outperform” rating in a research note on Tuesday, June 30th. Weiss Ratings restated a “sell (d-)” rating on shares of NewAmsterdam Pharma in a research report on Friday, July 17th. Finally, BMO Capital Markets started coverage on NewAmsterdam Pharma in a research note on Monday, July 20th. They set an “outperform” rating and a $58.00 price objective for the company. Two investment analysts have rated the stock with a Strong Buy rating, ten have given a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and a consensus target price of $49.42.

NewAmsterdam Pharma Stock Performance

NAMS opened at $30.22 on Tuesday. The firm’s fifty day moving average is $32.73 and its two-hundred day moving average is $32.84. The firm has a market cap of $3.53 billion, a PE ratio of -16.88 and a beta of 0.08. NewAmsterdam Pharma Company N.V. has a twelve month low of $21.14 and a twelve month high of $42.21.

NewAmsterdam Pharma (NASDAQ:NAMS) last announced its quarterly earnings results on Tuesday, March 31st. The company reported ($0.40) earnings per share for the quarter. NewAmsterdam Pharma had a negative return on equity of 26.49% and a negative net margin of 943.23%.The firm had revenue of $3.04 million for the quarter. Equities analysts forecast that NewAmsterdam Pharma Company N.V. will post -1.78 EPS for the current fiscal year.

Insider Buying and Selling

In other NewAmsterdam Pharma news, CAO Louise Frederika Kooij sold 40,000 shares of NewAmsterdam Pharma stock in a transaction dated Monday, June 22nd. The stock was sold at an average price of $30.20, for a total transaction of $1,208,000.00. Following the transaction, the chief accounting officer directly owned 24,353 shares in the company, valued at approximately $735,460.60. The trade was a 62.16% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. Insiders own 12.74% of the company’s stock.

NewAmsterdam Pharma Profile

NewAmsterdam Pharma, Inc is a clinical‐stage biopharmaceutical company focused on discovering and developing novel small‐molecule therapies for cardiometabolic diseases. The company’s research efforts are aimed at addressing key unmet needs in metabolic syndrome, obesity and type 2 diabetes by modulating pathways involved in glucose regulation, energy homeostasis and lipid metabolism.

The company’s development pipeline features multiple small‐molecule candidates at various stages of preclinical and clinical evaluation.